IP Library Patent Application 16517776
Patent Application
App. No. 16/517,776

METHOD OF PRODUCING ANTIBODIES WITH N-GLYCOSIDE-LINKED SUGAR CHAINS LACKING FUCOSYLATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/517,776
Abstract

The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.

Claims (11)

1 - 4 . (canceled)

5 . A method for producing an antibody composition, said method comprising:

(1) introducing a vector comprising a nucleotide sequence encoding an antibody into a host cell;

(2) culturing the antibody-producing host cell; and

(3) recovering the antibody from the culture supernatant,

wherein said antibody composition comprises antibody molecules having complex-type and/or hybrid-type N-glycoside-linked sugar chain in a Fc region, wherein all of said antibody molecules have two N-glycoside-linked sugar chains in which fucose is not bound (FO).

6 . The method according to claim 5 , wherein said antibody molecules comprise N-glycoside-linked sugar chains in which at least one N-acetylglucosamine is bound to a mannose at the non-reducing end of the following structure:

7 . The method according to claim 5 , wherein said antibody molecules comprise the complex-type N-glycoside-linked sugar chains in which two N-acetylglucosamine are respectively bound to two mannoses at the non-reducing end of the following structure:

8 . The method according to claim 5 , wherein said antibody molecules have an increased antibody dependent cellular cytotoxicity (ADCC).

9 . The method according to claim 5 , wherein said antibody molecules are molecules of a human antibody, a humanized antibody, a chimeric antibody or a human CDR-grafted antibody.

10 . The method according to claim 5 , wherein said antibody molecules are molecules of an IgG class antibody.